Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment
Yazar
Oreja-Guevara, C.
Bermel, R.
Comi, G.
Eralinna, J. -P.
Leist, T. P.
Nicholas, R.
Van Wijmeersch, B.
Wiendl, H.
Bernasconi, C.
Buffels, R.
Csoboth, C.
Han, J.
Musch, B.
Vermersch, P.
Siva, A.
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Bildiri [64839]